Compare AIRI & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRI | VTGN |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 10.8M |
| IPO Year | 2013 | 2014 |
| Metric | AIRI | VTGN |
|---|---|---|
| Price | $2.67 | $0.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $0.90 |
| AVG Volume (30 Days) | 25.9K | ★ 603.0K |
| Earning Date | 05-14-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,921,000.00 | N/A |
| Revenue This Year | $6.43 | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.30 | $0.20 |
| 52 Week High | $3.95 | $5.14 |
| Indicator | AIRI | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 41.03 |
| Support Level | $2.55 | $0.23 |
| Resistance Level | $2.76 | $0.32 |
| Average True Range (ATR) | 0.09 | 0.01 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 68.18 | 28.46 |
Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.